This trial was performed to determine the maximum tolerated whole-body radiation-
absorbed dose of fractionated 131I-cG250. Methods: This was a phase 1 dose escalation …

Clinical tumor targeting studies with chimeric monoclonal antibody G250 (cG250) in renal
cell carcinoma (RCC) patients indicated the potential use of this antibody for …

Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two
sequential high-dose treatments of radioimmunotherapy with [131I] cG250 in patients with …

Tumor uptake of the chimeric G250 (cG250) monoclonal antibody (mAb) in patients with
primary renal cell carcinoma (RCC) is among the highest reported in solid tumors. However …

Purpose: There is increasing evidence that the chimeric monoclonal antibody G250 (cG250)
can be internalized by G250 antigen-expressing renal cell carcinoma (RCC) cells. Thus …

Purpose A previous activity dose-escalation study using 131I-labeled chimeric monoclonal
antibody cG250 in patients with progressive metastatic renal cell carcinoma (RCC) resulted …

Results: In all patients with antigen-positive tumors (n= 13), the primary tumors and all
known metastases were clearly visualized. Overall uptake, expressed as the percentage of …

Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the
stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates (131I …

Abstract This Phase I/II radioimmunotherapy study was carried out to determine the
maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. Thirty-three patients …

This study aimed to estimate the radiation absorbed doses to normal tissues and tumor
lesions during radioimmunotherapy with 177Lu-cG250. Serial planar scintigrams after …